---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021495"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:36:53.147148+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics Q1 net loss $9.9M; cash $51.8M; REASSURE trial on track

## Summary
- Net loss Q1 2023 $9.9M vs $3.5M Q1 2022; non-GAAP net loss $7.4M vs $5.6M.
- Cash and investments $51.8M as of March 31, 2023; expected to fund operations until mid-2024.
- R&D expense $6.4M (up from $3.4M) due to REASSURE; G&A $2.1M (down from $3.9M).
- REASSURE trial enrollment ongoing; completion expected H1 2024; interim analysis H2 2023.
- Approximately 12.9M ordinary shares outstanding as of April 30, 2023.

## SEC filing metadata
- accession: 0000950170-23-021495
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/0000950170-23-021495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/itrm-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021495
- JSON: https://secwatch.observer/filing/0000950170-23-021495.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021495.txt

## Key facts
- Earnings Releases
  Iterum Therapeutics plc reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter 2023 was $9.9 million.
  - Period: first quarter ended March 31, 2023
  - Net income: Net loss for the first quarter 2023 was $9.9 million
  - Result: reported results
  source text: Iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/0000950170-23-021495-index.htm
- Earnings Releases
  Iterum Therapeutics plc reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter 2023 was $9.9 million.
  - Period: first quarter ended March 31, 2023
  - Net income: Net loss for the first quarter 2023 was $9.9 million
  - Result: reported results
  source text: Net loss for the first quarter 2023 was $9.9 million, compared to a net loss of $3.5 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/0000950170-23-021495-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.